Chad M Robins sold $2.4M of ADPT
CEO and Chairman at Adaptive Biotechnologies Corp. 285,187 shares at an average of $8.45, traded Feb 19, 2025, filed Feb 21, 2025.
Score components
- +25RoleCEO
- +25Trade size$2.4M at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-25-003241, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 19, 2025 | MOption exercise Common Stock10b5-1 | +186,080 | $6.32 | $1.2M | 2,762,781 | Feb 21, 2025 |
| Feb 19, 2025 | SOpen-market sale Common Stock10b5-1 | -186,080 | $8.46 | $1.6M | 2,576,701 | Feb 21, 2025 |
| Feb 20, 2025 | MOption exercise Common Stock10b5-1 | +99,107 | $6.32 | $626k | 2,675,808 | Feb 21, 2025 |
| Feb 20, 2025 | SOpen-market sale Common Stock10b5-1 | -99,107 | $8.44 | $836k | 2,576,701 | Feb 21, 2025 |
| Feb 19, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -186,080 | $0.00 | $0 | 99,107 | Feb 21, 2025 |
| Feb 20, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -99,107 | $0.00 | $0 | 0 | Feb 21, 2025 |
Related signals
Other insiders at Adaptive Biotechnologies Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $948k 35,643 shares | -9% | |
| 22Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $193k 6,444 shares | -2% | |
| 22Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $758k 26,792 shares | -11% | |
| 25Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $1.0M 35,643 shares | -9% | |
| 23Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $3.2M 115,406 shares | -34% | |
| 8Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $32k 1,195 shares | -0% | |
| 22Weak | ADPTsell Adaptive Biotechnologies Corp | Kyle Piskel Chief Financial Officer | $17k 1,929 shares | -1% | |
| 22Weak | ADPTsell Adaptive Biotechnologies Corp | Kyle Piskel Chief Financial Officer | $17k 1,929 shares | -1% | |
| 0Weak | Adaptive Biotechnologies Corp | Harlan S Robins Chief Scientific Officer | $503k 68,412 shares | -5% | |
| 0Weak | Adaptive Biotechnologies Corp | Harlan S Robins Chief Scientific Officer | $15k 1,698 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.